Chemify raises over £37m in Series B funding co-led by Wing Venture Capital and Insight Partners to expand its digital chemistry platform globally.
The oversubscribed round will scale automated laboratories and molecular design operations.
Chemify develops deep-tech systems that combine robotics, artificial intelligence and computation to digitise molecule creation and chemical synthesis. The company operates automated laboratory facilities designed to accelerate discovery for pharmaceutical and materials science partners.
Glasgow-based Chemify has secured over £37m in Series B funding to scale its digital chemistry platforms globally. The financing was co-led by Wing Venture Capital and Insight Partners, with additional participation from 8VC, Triatomic Capital, Blueyard, Rockspring and Eos.
The capital will support the international expansion of the company's Chemputation platform and automated Chemifarm facilities, which aim to transform molecular design and manufacturing for pharmaceuticals and advanced materials. As part of the expansion, Chemify plans to establish a facility in Silicon Valley.
Founded as a spin-out from the University of Glasgow, the company seeks to turn chemical discovery into a programmable science through robotics and artificial intelligence. Representatives from the co-leading investors have also joined the board of directors following the transaction.
From the founder
"Chemify aims to become the global digital backbone of chemistry, enabling fast design and discovery. Our vision is that Chemify will be able to design and make any molecule on demand for our customers across all of chemistry from drug discovery to new catalysts and electronic materials. The next step in our evolution is nothing short of a revolution in the digitization and automation of chemical discovery and manufacturing."
Lee Cronin
CEO and Founder at Chemify
Investor perspective
"Lee is an iconoclast with the wind at his back. Chemify’s use of AI to ensure the makeability of complex molecules is a paradigm shift for how medicinal chemistry is done today, and the company’s vision is matched by the strong results seen across their early pharma collaborations."
Aiden Aceves
Vice President, Insight Partners
Use of funds
- 01Expand into international markets
